The German Breast Group (study group) and GBG Forschungs GmbH work hand in hand with the aim of continually improving the treatment of breast cancer and the quality of the therapy available on a global basis. In order to achieve this goal, we conduct research within the context of academically orientated clinical trials. We work closely with research-based pharmaceutical companies and combine the latest active substances – enabling us to recommend the most effective forms of therapy.
As an independent academic research institute, we implement clinical trials in phases I to IV. Our field of research covers neoadjuvant drug therapy, operative therapy, post-operative adjuvant therapy and chronic palliative therapy.
Under the menu item “Trials”, you will find information about ongoing trials as well as trials currently in the follow-up phase. In addition, our “Trial Archive” contains details of trials already completed.
Overview of our currently recruiting trials. Further studies are in planning.
Operable node-positive breast cancer:
Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy. All patients will receive breast/chest wall and regional nodal irradiation. Patients without axillary lymph node dissection will receive additional irradiation of the axilla.
Operable HER2-positive or triple-negative breast cancer:
GBG104 - EUBREAST-01
Omission of sentinel lymph node biopsy in patients with radiologic and pathologic complete response in the breast after neoadjuvant systemic therapy. All patients with confirmed breast pCR after lumpectomy will be selected for the single study arm leading to omission of any axillary treatment.
HER2-positive, HR-positive breast cancer
GBG105 - GeparPiPPa
Arm A: Endocrine therapy in combination with ready-to-use fixed-dose combination of pertuzumab and trastuzumab s.c. (PH-FDC SC) q3w and inavolisib (6 cycles)
Arm B: Endocrine therapy and PH-FDC SC q3w (6 cycles)
HER2-negative breast cancer, non-pCR after NACT
GBG102 - SASCIA
Arm A: Sacituzumab govitecan 8 cycles d1,8 q3w
Arm B: Treatment of physician`s choice (8 cycles capecitabine or platinum-based chemotherapy or observation)
In patients with HR-positive breast cancer, endocrine therapy will be administered according to local guidelines.
HER2-positive breast cancer, non-pCR after NACT
GBG103 - TruDy/DESTINY-B05
Arm A: Trastuzumab deruxtecan 14 cycles d1 q3w
Arm B: Trastuzumab emtansine (T-DM1) 14 cycles d1 q3w
HR-positive / HER2-negative breast cancer:
GBG 111 – Flamingo-01 *
HLA-A*02 subjects will be randomized to GLSI-100 or placebo:
Arm A: 11 intradermal doses of placebo (NaCl 0.9%) over 3 years
Arm B: 11 intradermal doses of GLSI-100 (blinded) over 3 years
A third open-label arm will explore GLSI-100 in non-HLA-A*02 positive patients (11 intradermal doses of GLSI-100 over 3 years)
Brain metastases of breast cancer
GBG79 - Brain Metastases in Breast Cancer (BMBC)
Retrospective and prospective registry designed to collect tumor characteristics of the primary and metastatic tumor as well as treatment data and biomaterial from patients diagnosed with brain metastases of breast cancer.
HER2-negative and HR-positive metastatic breast cancer :
GBG93 - PADMA
Endocrine therapy + palbociclib versus mono-chemotherapy +/- endocrine maintenance therapy
Possible mono-chemotherapies (Physician`s choice):
GBG29 - BCP
Prospective and retrospective registry study for the diagnosis and treatment of breast cancer in pregnancy compared to young non-pregnant women.
GBG106 - BRCA-P *
Study to determine the preventive effect of denosumab on breast cancer in women carrying a BRCA1 germline mutation:
Denosumab 120mg s.c. every 6 months vs placebo s.c. every 6 months
GBG71 - Patient self-reported outcome registry (PSRO)
Collection of long-term safety and efficacy parameters of former GBG study participants from prospective clinical trials. Data reporting by the patient via questionnaire.
GBG107 - ETERNITYB
Registry for collection of long-term safety and efficacy parameters of former GBG study participants from prospective clinical trials. Data collection and documentation is performed study site.
* Planned start of recruitment QII-III/2023